English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The Alzheimer’s disease (AD) is a process that causes a progressive and irreversible decline of cognitive functions, which includes no organized behavior and psychotic symptoms. The progression of the disease symptoms is associated with structural changes in cholinergic synapses in certain brain regions and consequent impairment of cholinergic neurotransmission 1, 2 . The AD is complex, and nowadays the therapeutic treatment offers only limited and few benefits for the patients, so it is essential to search for alternative AD treatments. In this work, we summarize the synthesis of (4-piperidin-1-yl)-[(4-azidequinolin-2-yl)-methyl] methyl alcohol (8), as key intermediate to synthesize indanonebased hybrid (1) with potencial acetylcholinesterase inhibiton (Fig. 1) and to treat AD.

Studies toward an indanone-based hybrid with potencial AchE inhibition to treat Alzheimer’s disease